Dr. Sarah Nasser
PARSGO Executive Officer
Gynecological Oncology Fellow, Charité Comprehensive Cancer Center (Germany)
Member of the Royal College of Obstetricians & Gynaecologists (London)
International Journal of Gynecological Cancer Editorial Fellow
9:30-10:00
19 November 2022 Day 3
Patient-Reported Outcomes from the Phase 3 Randomized, Double-Blind, KEYNOTE-826 Trial of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer